Biosensors & bioelectronics · 2026
An artifact-resilient multimodal bioelectronic patch for monitoring biochemical and motor states in Parkinson's disease.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Geng Haoyang, Li Shiyao, Liang Changcheng, Min Shunhua, Sun Xin, Peng Yuyan, Ding Shichao, Wang Zhijun, Liu Yibiao, Liu Qingzhou, Xu Tailin
Аннотация
Personalized management of Parkinson's disease (PD) requires continuous tracking of motor fluctuations and medication-associated biochemical dynamics during daily living. Here, we report the Biochemical and Inertial Multimodal Assessment Patch (BIMAP), a fully integrated multimodal bioelectronic patch that combines multiplexed sweat biosensing of levodopa (L-Dopa), glucose (Glu), and ascorbic acid (AA) with triaxial accelerometry for biochemical-kinematic monitoring of PD-related states. A microfluidic sampling interface is incorporated to stabilize sweat transport and maintain sensor-fluid contact during motion. We further develop a machine-learning-assisted Multimodal Adaptive Gating Network (MAG-Net) to adaptively weight biochemical and inertial features according to the instantaneous motion state. This strategy reduces the contribution of motion-perturbed electrochemical features, while retaining L-Dopa-related biochemical context for distinguishing medication-associated motor changes from frequency-matched daily activities. On-body feasibility tests involving healthy volunteers and participants with PD showed that the patch could track intake-associated biochemical changes and temporally aligned changes in estimated sweat L-Dopa and motor activity after medication administration. The multimodal signals further enabled exploratory discrimination of four protocol-defined medication-motion states under the tested conditions. These results support the feasibility of artifact-resilient biochemical-kinematic monitoring in wearable settings.